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dermatitis of horses occurring upon insect bites. In recent years, a major role for IL‐31 in allergic
pruritus of humans, monkeys, dogs and mice was acknowledged. Objective Here, we investigate the role
of IL‐31 in IBH of horses and developed a therapeutic vaccine against equine IL‐31 (eIL‐31). Methods
IL‐31 levels were quantified in allergen‐stimulated PBMCs and skin punch biopsies of IBH lesions and
healthy skin from IBH‐affected and healthy horses. The vaccine consisted of eIL‐31 covalently coupled
to a virus‐like particle (VLP) derived from cucumber mosaic virus containing a tetanus toxoid universal
T‐cell epitope (CuMVTT). Eighteen IBH‐affected horses were recruited and immunized with 300 ฀g of
eIL‐31‐CuMVTT vaccine or placebo and IBH severity score was recorded. Results IL‐31 was increased
in PBMCs and exclusively detectable in skin lesions of IBH‐affected horses. Vaccination against eIL‐31
reduced delta clinical scores when compared to previous untreated IBH season of the same horses and
to placebo treated horses in the same year. The vaccine was well tolerated without safety concerns
throughout the study. Conclusion TH2‐derived IL‐31 is involved in IBH pathology and accordingly the
immunotherapeutic vaccination approach targeting IL‐31 alleviated clinical scores in affected horses.
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ABSTRACT (203 words)
Background: Insect bite hypersensitivity (IBH) is the most common seasonal pruritic allergic 
dermatitis of horses occurring upon insect bites. In recent years, a major role for IL-31 in allergic 
pruritus of humans, monkeys, dogs and mice was acknowledged. 
Objective: Here, we investigate the role of IL-31 in IBH of horses and developed a therapeutic 
vaccine against equine IL-31 (eIL-31).
Methods: IL-31 levels were quantified in allergen-stimulated PBMCs and skin punch biopsies of 
IBH lesions and healthy skin from IBH-affected and healthy horses. The vaccine consisted of eIL-
31 covalently coupled to a virus-like particle (VLP) derived from cucumber mosaic virus 
containing a tetanus toxoid universal T-cell epitope (CuMVTT). Eighteen IBH-affected horses 
were recruited and immunized with 300 μg of eIL-31-CuMVTT vaccine or placebo and IBH 
severity score was recorded.
Results: IL-31 was increased in PBMCs and exclusively detectable in skin lesions of IBH-
affected horses. Vaccination against eIL-31 reduced delta clinical scores when compared to 
previous untreated IBH season of the same horses and to placebo treated horses in the same year. 
The vaccine was well tolerated without safety concerns throughout the study.  
Conclusion: TH2-derived IL-31 is involved in IBH pathology and accordingly the 
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INTRODUCTION
The inflammatory Interleukin 31 (IL-31) belongs to the gp130/IL-6 cytokine family and is 
associated with cellular immunity against pathogens and numerous chronic inflammatory diseases 
(Bagci and Ruzicka, 2018; Dillon et al., 2004; Pflanz et al., 2004; Zhang et al., 2008). The main 
source of IL-31 is type 2 helper T- (TH2) cells, however, to a lesser extent other sources such as 
mature dendritic cells (DCs) have also been described (Cevikbas et al., 2014; Sonkoly et al., 
2006). IL-31 signaling is initiated when binding to its receptor complex composed of the IL-31 
receptor A (IL-31RA) that heterodimerizes with the oncostatin M receptor β (OSMRβ). 
Downstream intracellular signaling involves the activation of Janus kinase-signal transducer and 
activator of transcription (JAK-STAT), mitogen-activated protein kinase (MAPK), and 
phosphatidylinositol 3-kinase (PI3K) pathways. Epithelial cells constitutively express IL-31RA 
and OSMRβ, whereas monocytes only do when activated (Zhang et al., 2008). Other cell types 
including keratinocytes, macrophages, and eosinophils also do express the IL-31 receptor complex 
(Kasraie et al., 2011; Kasraie et al., 2010; Zhang et al., 2008). Moreover, a subset of nociceptive 
neurons in the dorsal root ganglia (DRG) express the receptor, thus allowing a direct targeting of 
peripheral nerves by the immune system (Mizuno et al., 2009; Sonkoly et al., 2006). Hence, IL-31 
directly links the immune system and the nervous system. Indeed, it is well appreciated that IL-31 
is involved in the induction of pruritus leading to itchy skin in an allergic TH2-context, which, 
however, was shown to be independent of mast cell or basophil degranulation or proteinase-
activated receptor-2 (PAR-2) (Cevikbas et al., 2014; Sonkoly et al., 2006). Transgenic mice 
overexpressing IL-31 develop strong pruritus, as well as skin lesions often with hair loss, 
histologically characterized by increased inflammatory cell infiltration (Dillon et al., 2004). 
Intradermal injection of IL-31 was further shown to induce itch and consecutive scratching in 
murine wild type (WT) skin (Cevikbas et al., 2014). In addition, in humans IL-31 expression was 
shown in skin-homing CD45RO+ memory cutaneous lymphocyte-associated antigen (CLA)-
positive T cells derived from patients with atopic dermatitis. Also, in patients with atopic 
dermatitis, 60% of TH2 cells abundant in the dermis were positive for IL-31 (Cevikbas et al., 
2014).
Insect bite hypersensitivity (IBH) in horses is the most common skin allergy of horses and is 
caused by insect bites. Clinical signs typically occur along the dorsal and ventral bodyline. The 
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eczema-like, with hyperkeratotic scales, bloody crust formation and lichenification in chronic 
phases (Anderson et al., 1991; Baker and Quinn, 1978; Braverman et al., 1983; Fadok and 
Greiner, 1990; Greiner et al., 1990; Kurotaki et al., 1994; Quinn et al., 1983; Schaffartzik et al., 
2012). The disease is characterized by type I/IVb allergic reactions with accompanied eosinophil 
infiltration into the skin (Benarafa et al., 2002; Fettelschoss-Gabriel et al., 2018; McKelvie et al., 
1999; RF, 1953). Upon insect bites, allergic horses suffer from strong pruritus leading to intense 
scratching and self-inflicted skin destruction thereby amplifying the allergic symptoms. 
Previously, thymic stromal lymphopoietin (TSLP) and monocyte chemoattractant protein 1 (MCP-
1) (or CCL2) were associated with IBH disease pathology (Benarafa et al., 2002; Klumplerova et 
al., 2013; Vychodilova et al., 2013). The role of IL-31 in pruritic IBH lesions of the horse remains 
elusive. Similar to our earlier described therapeutic vaccine targeting equine IL-5 (eIL-5) in order 
to reduce eosinophil production and infiltration into the skin, we developed a therapeutic vaccine 
targeting equine IL-31 (eIL-31). The earlier described virus-like particle (VLP)-based eIL-5-
CuMVTT vaccine was able to reduce IBH disease symptoms and even could show enhanced 
improvement of disease scores in a second follow-up treatment year (Fettelschoss-Gabriel et al., 
2019; Fettelschoss-Gabriel et al., 2018). Accordingly, we performed a placebo-controlled double-
blind randomized clinical study in IBH-affected horses to evaluate the therapeutic potential of 
targeting IL-31. Our results suggest a prominent role for IL-31 in IBH disease pathology further 











This article is protected by copyright. All rights reserved
MATERIALS & METHODS
Horses. All horses were privately held client-owned horses, all horse owners signed informed 
consent. IBH-affected horses showed recurrent seasonal clinical signs of IBH at least one season 
prior to untreated first evaluation season; healthy horses were IBH symptom-free at sample 
collection and had no history of IBH. All interventions and clinical studies were approved by the 
cantonal veterinary authorities. Sample collection, PBMCs and biopsies. PBMCs were collected 
from 19 IBH affected horses and three healthy horses. Biopsies were collected from seven IBH 
affected horses and four healthy horses. From IBH affected horses, one biopsy was taken from 
lesional and one from non-lesional skin. Clinical study horses. Case study: A single IBH-affected 
Icelandic horse was recruited to the case study. The study consisted of two years with a first 
observational untreated season (“untreated”) and a second season including vaccination 
(“vaccinated”). In both seasons the horse health was checked daily and the IBH severity was 
scored at least monthly from March until October. Double blind placebo-controlled randomized 
trial: Eighteen IBH-affected horses were recruited to a double-blind placebo-controlled 
randomized clinical study, nine horses received vaccine, nine horses received placebo. The study 
consisted of two years, the recruitment and observational year and the treatment year including 
double-blind vaccinations. The clinical study was performed as double-blind placebo-controlled 
randomized trial, neither the person that performed the clinical trial nor the horse owners knew in 
which group the horses were. The independent vaccine filler has randomized the study and was 
not involved in any clinical part of the study. Prior to first vaccination and in a monthly fashion 
post second vaccination serum was withdrawn for antibody titer measurement. IBH lesions were 
scored monthly during observation period from March until October. Design of the clinical study 
is illustrated in the online Supplementary Fig 1.
Allergen stimulation in vitro. Peripheral blood mononuclear cells (PBMCs) were isolated using 
Biocoll gradient in complete RPMI Glutamax 1640 medium (Sigma Aldrich, Switzerland) and for 
24 hours stimulated with whole body extract (WBE) of Culicoides nubeculosus (5 μg/mL, (Peeters 
et al., 2013), Greer, USA), Concanavalin A (ConA, 5 μg/mL, Sigma Aldrich) or medium. Cells 
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Punch Biopsies. Punch biopsies (2 mm) from lesions of IBH-affected horses, from non-lesional 
skin of IBH-affected horses and healthy skin of healthy non-IBH horses were collected into 
RNAlaterTM Stabilization Solution (Thermo Fisher, USA) for RNA extraction.
RNA extraction and qPCR. Total RNA was extracted using RNAqueous-Micro Kit 
(ThermoFisher, USA) for punch biopsies and NucleoSpin® RNA XS Kit (Macherrey-Nagel, 
Germany) for PBMCs. Extractions were performed according to manufacturer’s protocol 
including DNase I treatment and inactivation. RNA was transcribed into cDNA using Reverse 
Transcription System (Promega, USA). All qPCR experiments were performed using FastStart 
Universal SYBR Green Master (Roche, Switzerland) with duplicate samples on a Viia7 Real-Time 
PCR System (ThermoFisher, USA). Gene expression levels were normalized by β-actin 
expression. Primers are listed in Table 1, supplementary information. IL-4 and IL-31 primer were 
designed by us; β-actin (Bogaert et al., 2006), MCP-1 (Benarafa et al., 2000), and TSLP 
(Klukowska-Rotzler et al., 2012) were previously published.
Cloning, expression and purification of recombinant eIL-31. The DNA sequence encoding for 
mature equine IL-31 (UniProt F7AHG9) was generated by gene-synthesis. In addition, a three 
amino acid linker (GGC) was added C-terminally and termed eIL-31-C-His. This insert was 
flanked by 5’ NdeI and 3’ XhoI and was integrated into pET 42b (+), containing a hexa His-tag 
and an in-frame stop codon. The resulting eIL-31 fusion protein was expressed in Escherichia coli 
BL21 (T7 Express C2566I) cells. Cell culturing, induction, harvest, inclusion body preparation 
and affinity tag purification were performed as described in (Fettelschoss-Gabriel et al., 2018). 
Subsequently, eIL-31 was refolded by sequential dialysis against the following buffers at pH 8.5 at 
4°C: B1 (2 M Urea, 50 mM NaH2PO4, 5 mM Glutathione reduced, 0.5 mM Gluthatione oxidized, 
0.5 M Arginine, 10 % Glycerol), B2 (50 mM NaH2PO4, 5 mM Glutathione reduced, 0.5 mM 
Gluthatione oxidized, 0.5 M Arginine, 10 % Glycerol), B3a (50 mM NaH2PO4, 0.5 M Arginine, 
10 % Glycerol), B3b (50 mM NaH2PO4, 10 % Glycerol), B4 (PBS). Finally, refolded protein was 
concentrated and purified on a HiLoad 26/600 Superdex 75 prep grade (GE Healthcare) with PBS 
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Circular dichroism (CD) spectroscopy of eIL-31-C-His. The far-UV CD spectrum of purified 
monomeric and dimeric eIL-31-C-His (in PBS) were measured on a J-710 spectropolarimeter 
(Jasco) at 25°C using a 1 mm cuvette. After correction for the buffer spectrum, ellipticity was 
converted to mean residue ellipticity as described (Milburn et al., 1993).
Coupling of eIL-31 to CuMVTT. CuMVTT VLP reacted with a 7.5-fold molar excess of the 
heterobifunctional cross linker succinimidyl-6(β-maleimidopropionamido)hexanoate (SMPH) in 
20 mM NaP/2 mM EDTA, pH 7.5 at 25°C (Pierce). Unreacted cross linker was removed by 
passage over a PD-10 desalting column (GE Healthcare). The recombinant, purified and refolded 
monomeric and dimeric eIL-31-C-His (1:1 ratio) were reduced for 1h with an equimolar amount 
of tri(2-carboxyethyl)phosphine hydrochloride (TCEP) in 20 mM NaP/2 mM EDTA, pH 7.5. The 
reduced eIL-31-C-His was then mixed with the derivatized CuMVTT VLPs at a molar ratio of 2:1 
and co-incubated for 4 hours at 22°C in 20 mM NaP/2 mM EDTA, pH 7.5. Vaccine was purified 
on a HiLoad 26/600 Superdex 75 prep grade (GE Healthcare) with 20 mM NaP/2 mM EDTA, pH 
7.5.
Vaccine analysis by SDS-PAGE, Coomassie staining and Western Blot. Described in 
(Fettelschoss-Gabriel et al., 2018).
Electron Microscopy (EM) of CuMVTT and eIL-31-CuMVTT. Samples were applied onto 
Formvar-coated 300-mesh Cu-grids (Plano, Germany) at a concentration of 0.1 mg/ml and 
incubated for 1 min at room temperature. Grids were stained with 1 % uranyl acetate solution for 1 
min before being dried for 30 min. Stained grids were observed under a 100 kV CM100 
transmission electron microscope (FEI, USA). Imaging was performed by support of the Center 
for Microscopy and Image Analysis, University of Zurich.
IBH lesion scoring. Described in (Fettelschoss-Gabriel et al., 2018). The delta (Δ) lesion score 
was calculated for placebo-treated and vaccinated horses as follows: For each horse and each 
measurement value of observational season was subtracted from corresponding vaccine season 
value. Many of the horses were recruited in the second half of the observational year; therefore we 
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Blood samples from horses. Blood was collected from V. jugularis. Sterile blood collection for 
PBMCs with NH Sodium Heparin VACUETTE ® container (Greiner Bio-one, Austria); non-
seterile blood collection for serum with serum tubes (IDEXX Diavet, Switzerland), centrifuged 
(3000 rpm, 10 min) and transferred into fresh tubes.
Vaccine administration, immunization regimen. Horses were injected subcutaneously with 300 
μg of eIL31-C-His-CuMVTT VLP in 1’000 μl of 20 mM NaP/2 mM EDTA, pH 7.5 without 
additional adjuvants. Horses received a prime-boost vaccination in weeks 0, 4 and a booster in 
week 19 (June).
Anti-CuMVTT and anti-IL-31 antibody titer. Maxisorp 96 well ELISA plates (Nunc) were coated 
over night with purified eIL-31-C-His or purified CuMVTT (5 mg/L) and continued as described in 
(Fettelschoss-Gabriel et al., 2018). Absorbance was measured at 450 nm by Tecan Spark 10M 
spectrophotometer (Tecan, Austria). The antibody titers as OD50 were calculated (serum dilution 
on a logarithmic scale where OD450 was half maximal). All antibody titers were calculated with 
naïve serum subtracted on logarithmic scales, and presented as delta OD50 (ΔOD50). Titers ≤ 10 
were considered background.
Statistics. All graphs comparing vaccinated horses versus placebo horses show mean and standard 
error of mean (SEM). PBMCs: Statistical analysis was performed by 2way ANOVA and if 
significant followed by Tukey’s multiple comparisons test. Skin Biopsies: Statistical analysis was 
performed by Kruskal Wallis test and if significant followed by Dunn’s multiple comparisons test. 
Placebo-controlled clinical trial: Statistical analysis were performed by two-tailed Wilcoxon test 
comparing lesion scores per month during untreated and treated IBH season. Considered to be 










This article is protected by copyright. All rights reserved
RESULTS
IL-31 expression in PBMCs and skin of healthy and IBH-affected horses
PBMCs were isolated from IBH-affected and healthy horses and stimulated with the IBH allergen 
Culicoides nubeculosus (Cul n) extract or medium control. Due to the lack of monoclonal 
antibodies, we performed qPCR for quantification of equine cytokines. Cul n stimulated PBMCs 
from IBH-affected horses showed increased levels of IL-31 when compared to Cul n stimulated 
PBMCs from healthy horses. Moreover, there was no difference of IL-31 levels in healthy horses 
when stimulating with the allergen or medium control. IBH-affected PBMCs showed increased 
IL-31 levels upon Cul n stimulation compared to medium stimulated cells (Fig 1A). Concanavalin 
A (Con A) stimulation triggered similar levels of IL-31, IL-4 and Stat5a RNA in IBH and healthy 
horses showing comparable quality of PBMCs (Fig 1B). Donor matched skin punch biopsies from 
IBH-affected horses were taken from IBH lesions and from non-lesional skin. In addition, we 
collected biopsies from healthy skin in healthy horses. Equine cytokines IL-31, TSLP, and MCP-1 
were quantified by qPCR in relation to housekeeping gene β-actin. IL-31 was solely detectable in 
IBH-affected skin, whereas it was neither detectable in non-lesional skin of IBH-horses nor in 
healthy skin of healthy horses (Fig 1C). In addition, we also found a trend towards higher levels of 
TSLP (Fig 1D) and MCP-1 (Fig 1E) in IBH lesions when comparing to healthy skin of IBH- or 
healthy horses. 
IL-31 and vaccine production
Recombinant eIL-31 with a C-terminal linker containing a free cysteine residue and a His-Tag 
(eIL-31-C-His) was generated by gene synthesis for protein production in E.coli. Purification and 
refolding steps are shown in Fig 2A. Far-UV circular dichroism (CD) spectroscopy revealed 
mostly α-helical secondary structures of the refolded eIL-31-C-His indicated by the minimax 
points at 208 and 222 nm (Fig 2B).
Chemical coupling of eIL-31-C-His to CuMVTT VLPs was induced by a heterobifunctional cross-
linker. Derivatization of the VLP showed the typical “VLP-ladder” caused by crosslinking of 
monomeric and multimeric CuMVTT subunits (Fig 2C, lane 2). Coupling of CuMVTT subunits 
with eIL-31-C-His molecules (Fig 2C, lane 1) led to additional coupling bands with a protein size 
corresponding to the molecular mass of monomeric or monomeric/dimeric eIL-31-C-His plus 
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eIL-31-C-His to CuMVTT was confirmed by Coomassie staining (Fig 2C) and Western blot using 
an anti-His antibody (Fig 2D). Coupling efficiency for all batches was between 20 to 50%, i.e. 
approximately 30 – 75 eIL-31 monomer and 15 – 40 eIL-31 dimer molecules per VLP (1:1 ratio of 
eIL-31 monomer and dimer). A further vaccine polishing step by size exclusion chromatography 
was performed to remove free uncoupled eIL-31-C-His from the vaccine (Fig 2C&D, lane 4&5). 
Integrity of CuMVTT VLPs before and after coupling was analyzed and confirmed by EM (Fig 2E, 
CuMVTT, Fig 2F, eIL-31-CuMVTT).
Anti-IL-31 and anti-CuMVTT antibody titers in horses
Antibody titers in serum of horses were evaluated monthly. Nine horses received a basic 
vaccination consisting of three immunizations, in weeks 0, 4 and 19 (June 1). Anti-CuMVTT 
antibody titers of vaccinated horses were used as surrogate marker for successful vaccination as 
the immune system is expected to readily induce antibodies against the foreign CuMVTT particles. 
All nine vaccinated horses developed antibodies against both IL-31 (Fig 3A&C) and CuMVTT (Fig 
3B&D). Comparably to our previously published eIL-5-CuMVTT vaccine (Fettelschoss-Gabriel et 
al., 2019; Fettelschoss-Gabriel et al., 2018), antibodies against eIL-31 and CuMVTT can be 
observed already after the second vaccination, however, are not yet long lasting and a booster mid-
season was required (Fig 3A&C). Of note, upon booster a single horse did only re-induce anti-
CuMVTT but not anti-IL-31 antibody titers.
Efficacy of eIL-31-CuMVTT vaccine by reduction of lesion scores 
Case study. Lesion scores of a single IBH-affected Icelandic horse were recorded in regular 
intervals in an untreated first IBH season (Fig 4A, untreated, grey), and a second IBH season with 
first year vaccination regimen using the eIL-31-CuMVTT vaccine (Fig 4A, vaccinated, black). The 
horse was vaccinated two times prior to IBH season start, which potentially delayed onset of IBH 
clinical signs. The booster vaccination in the middle of the IBH season further reduced IBH lesion 
scores during the vaccination year (Fig 4A). The anti-IL-31 antibody titer of that horse showed a 
strong, however, rapidly declining titer against IL-31 and CuMVTT VLP after the second 
vaccination, and a booster effect upon mid-season third vaccination, which also declined towards 
season end (Fig 4B).
Double blind placebo-controlled randomized trial. Nine eIL-31-CuMVTT vaccine horses and nine 
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year vaccination regimen. In the first vaccination year we established immunity against the 
vaccine by a total of three vaccine injections. Antibody titers were shown in Figure 3. We 
compared lesion scores from the third mid-season injection onwards, i.e. from June until October 
in untreated previous season and from June until October in vaccination season. No significant 
differences were found in the placebo group when comparing lesion scores from untreated and 
placebo treated season (Fig 4C). In contrast, significant differences were found in July and August 
in eIL-31-CuMVTT group when comparing scores from untreated and vaccine treated season (Fig 
4D). In October lesion scores of both groups improved independent of treatment when compared 
to the respective untreated seasons (Fig 4C&D). The delta lesion scores show the difference 
between both seasons. Mean delta lesion score of placebo horses was rather constant, indicating 
comparable clinical signs in both seasons (Fig 4E, grey). Mean delta lesion score of vaccinated 
horses was reduced upon booster vaccination in June, indicating improved clinical signs during 
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DISCUSSION
The present study demonstrates involvement of IL-31 in the pathophysiology of IBH. In vitro 
allergen-stimulated PBMCs from IBH-affected horses and skin biopsies from IBH lesions showed 
a prominent role for IL-31. In healthy horses only low levels of IL-31 were detectable in allergen-
stimulated PBMCs and moreover, IL-31 was completely absent in skin biopsies from non-lesional 
or healthy skin. Moreover, we found a trend towards higher levels of TSLP and MCP-1 in IBH-
lesions compared to healthy skin, confirming earlier suggested data (Benarafa et al., 2002; 
Klumplerova et al., 2013; Vychodilova et al., 2013). TSLP in the skin mainly derives from 
epithelial cell upon skin barrier disruption; MCP-1 recruits monocytes, dendritic cells and memory 
T cells to inflammatory tissue sites, thus both contributing to the exacerbation of allergy. In a case 
report and a placebo-controlled double-blind clinical trial, eIL-31-CuMVTT vaccinated IBH-
affected horses developed anti-IL-31-specific antibodies and showed improved clinical signs 
compared to placebo treated IBH-affected horses and previous untreated season. No safety 
concerns occurred throughout the clinical trials. Similar to the eIL-5-CuMVTT vaccine, two initial 
vaccinations of eIL-31-CuMVTT were sufficient to induce auto-antibodies against IL-31 and the 
third injection prolonged antibody titers throughout the IBH season (Fettelschoss-Gabriel et al., 
2019). Anti-CuMVTT antibody titers against the foreign VLP as surrogate marker demonstrate 
successful vaccination. In contrast, detection of anti-IL-31 antibodies could be masked by anti-IL-
31 antibody / IL-31 antigen complexes in the serum leading to different rates of anti-IL-31 
antibody depletion. Along these lines it is likely that anti-IL-31 antibody levels require a certain 
threshold to be protective rather than showing a linear dependency. Also, allergen exposure levels 
during the IBH season are not constant and vary with weather conditions and activity of the 
midges. For example, seasonal dynamics of the main trigger associated with IBH Culicoides spp. 
show highest activity in spring and in autumn (Sanders et al., 2011) leading to varying intensities 
of allergic symptoms including varying levels of associated effector molecules.
IBH is defined as type I allergy with type IVb characteristics (Benarafa et al., 2002; Fettelschoss-
Gabriel et al., 2018; McKelvie et al., 1999; RF, 1953). Type I pathology includes IgE-mediated 
mast cell and basophil activation when allergen-specific IgE binds to its Fc ε receptor type I 
(FcεRI), leading to histamine release from cellular granules (Prussin and Metcalfe, 2003). 
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recommended for IBH therapy (Olsen et al., 2011). This led to the assumption that there might be 
an additional causative mediator for the allergic itch. IL-31 is a TH2 cell derived cytokine, 
mediating pruritus by targeting peripheral nerves and acting independent of histamine (Cevikbas 
et al., 2014).
In humans IL-31 appears to be involved in the pruritus development of patients with several skin 
diseases such as atopic dermatitis, psoriasis or lupus erythematodes (Huang et al., 2016; Lu et al., 
2018; Nattkemper et al., 2018; Siniewicz-Luzenczyk et al., 2013). A monoclonal antibody (mAb) 
against human IL-31 receptor (Nemolizumab, Chugai Pharma) for the treatment of pruritus in 
atopic dermatitis entered clinical testing in 2012 and significantly reduced itching, however, did 
not improve eczema (Ruzicka et al., 2017). A human double-blind safety study of Nemolizumab 
administered every four or eight weeks for up to 64 weeks was well tolerated in patients with 
moderate-to-severe atopic dermatitis and was without any safety concerns. Furthermore, an anti-
IL-31 mAb by Bristol-Myers Squibb completed clinical phase 1 study in healthy subjects and 
adults with atopic dermatitis in 2015 and so far without safety concerns. In animals, Zoetis Inc 
developed an anti-canine IL-31 mAb (Lokivetmab, Cytopoint®), which recently entered the 
market as a treatment of atopic dermatitis in dogs. Such antibody treatment is expected to have 
fewer side effects than the currently used JAK inhibitor (Oclacitinib, APOQUELTM). Regarding 
therapy costs and given the size and weight of a horse, systemically daily chemical inhibition of 
JAK or intravenous monthly monoclonal antibody injections, both applied based on body weight, 
limit the choice of therapeutics to the class of vaccines, which are applied at low dose and will be 
injected subcutaneously for three times in the first year and a single booster in the following years 
(Fettelschoss-Gabriel et al., 2019). Moreover, vaccines induce self-made polyclonal active 
immunity with additive neutralization capacities over blocking a single epitope, i.e. by passive 
immunity transfer of mAbs. In addition, mAbs commonly have a modified protein sequence 
adjusting the use to the target species such as humanization; thus, equine mAbs would need an 
“equinization”. However, 786 existing equine breeds (2006, FAO Global Data Bank) will turn this 
into a very complex task. Even in humans humanization can be challenging and a common side 
effect is the development of anti-therapeutic antibodies limiting the choice of therapeutics in 
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To our knowledge, we first describe a role for IL-31 in IBH and the eIL-31-CuMVTT vaccine is 
the first therapy targeting IL-31 in horses. It is the second therapeutic vaccine proposed for the use 
in IBH-affected horses, besides our recently described eIL-5-CuMVTT vaccine (Fettelschoss-
Gabriel et al., 2019; Fettelschoss-Gabriel et al., 2018). Whilst the eIL-5-CuMVTT vaccine targets 
the allergy-associated hyper-eosinophilia and thereby reduces the number of toxic cells potentially 
causing tissue damage of the skin, the eIL-31-CuMVTT vaccine rather targets the allergic itching 
caused by the underlying allergic immune response in the skin. Comparably to the mAb against 
IL-31 we suggest that the vaccine-induced anti-IL-31 antibodies mitigate the IL-31-mediated 
pruritus (Gonzales et al., 2016; Lewis et al., 2017) and thus lowering the self-inflicted trauma 
caused by the horse scratching its skin. When comparing the clinical benefit of blocking IL-31 in 
horses with other species, we noticed a reduction of skin lesion severity in IBH-affected horses, 
which, is in contrast to atopic dermatitis trials in dogs and humans that only showed reduction of 
pruritus whereas no improvement of eczema (Ruzicka et al., 2017; Tamamoto-Mochizuki et al., 
2019). This suggests a meaningful impact of the self-inflicted trauma in horses with IBH. 
Although an anti-IL-31 therapy will not prevent the allergic reaction itself, it might represent an 
option stopping the vicious circle of self-reinforcing pruritus to alleviate clinical symptoms. 
Taken together, eIL-31-CuMVTT successfully induced autoantibodies against IL-31 and 
simultaneously reduced lesion scores in vaccinated horses when compared to placebo treated 
horses. This is the second anticytokine vaccine that has shown clinical efficacy for the treatment 
of a disease in the target species horse and might facilitate the development of a similar vaccine 
targeting IL-31 in human or other companion animal subjects. The next step will be the 
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FIGURE LEGENDS
FIG 1. IL-31 expression in IBH-affected skin and allergen stimulated PBMCs. A. & B. 
Culicoides nubeculosus (Cul n) (A.) or Con A (B.) allergen extract stimulated PBMCs from IBH-
affected horses (IBH, n=19) and healthy horses (Healthy, n=3). A. Percentage of eIL-31 
expression levels relative to eβ-actin levels upon Cul n stimulation. B. Percentage of eIL-31, eIL-
4, and Stat5a expression levels relative to eβ-actin levels upon Con A stimulation. C. & D. & E. 
Two mm skin punch biopsies from IBH-affected skin (n=7), healthy skin from IBH-affected 
horses (n=7) and healthy skin from healthy non-IBH horses (n=4). Quantification of eIL-31 (C.), 
eTSLP (D.), and MCP-1 (E.) levels by qPCR shown as percent expression of eβ-actin 
housekeeping gene, of skin biopsies taken from IBH lesion sites (n=7), matched healthy skin from 
the same horses (n=7), and healthy skin from healthy horses (n=4).
FIG 2. EIL-31 and eIL-31-CuMVTT vaccine. A. SDS-PAGE analysis of eIL-31-C-His. Samples 
from various stages of the inclusion body preparation and purification were applied to a 4-12% 
B/T gel and run under reducing conditions. Proteins were stained with Coomassie blue. Lane M, 
Size Marker, lane 1, Lysate (sample A), lane 2, soluble fraction (sample B), lane 3, solubilized 
inclusion bodies (sample C), lane 4, flow through (unbound material, sample D), lane 5, pooled 
eIL-31 monomer (eIL-31, m) eluate from Ni-NTA column (sample E), lane 6, pooled eIL-31 
monomer and dimer eIL-31 (eIL-31, d) after refolding and size exclusion chromatography (sample 
F), lane 7, sample F run under native conditions (sample G). B. Far-UV circular dichroism (CD) 
spectrum of purified eIL-31-C-His monomer (eIL-31-m) and dimer (eIL-31-d). C. & D. SDS-
PAGE of eIL-31-CuMVTT. Lane M, Size Marker, lane 1, TCEP activated eIL-31-C-His, lane 2, 
CuMVTT-VLP after derivatization with the chemical crosslinker SMPH, lane 3, eIL-31-C-His-
CuMVTT coupling reaction, lane 4, eIL-31-C-His-CuMVTT vaccine post size exclusion 
chromatography (SEC), lane 5, free eIL-31 removed from eIL-31-C-His-CuMVTT vaccine during 
SEC. eIL-31-C-His, CuMVTT, and eIL-31-CuMVTT were loaded equimolar in order to compare 
coupling efficacy. C. Proteins were stained with Coomassie blue. eIL-31 monomer (eIL-31, m), 
eIL-31 dimer (eIL-31, d), coupling (c). D. WB of eIL-31-CuMVTT. Stained with α-His antibody. 
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FIG 3. Antibody titer of vaccinated horses against eIL-31 and CuMVTT-VLP. Vaccinations are 
indicated by grey arrows. A. Antibody titer of anti-eIL-31 IgG of single horses. B. Antibody titer 
of anti-CuMVTT IgG of single horses. C. Mean antibody titer of anti-eIL-31 IgG with SEM. D. 
Mean antibody titer of anti-CuMVTT IgG with SEM. All antibody titers are calculated with naïve 
serum subtracted on logarithmic scales, limit of detection are titers ≤ 10.
FIG 4. Efficacy of eIL-31-CuMVTT vaccine by reduction of lesion scores. A. & B. Case report. 
A. IBH lesion scores of single horse during untreated previous season (grey) and vaccination 
season (black). B. Antibody titer against eIL-31 (left y-axis, black) and CuMVTT (right y-axis, 
grey) of single horse. Vaccinations are indicated by arrows. C-E. Double blind placebo-controlled 
randomized clinical study. C. Monthly lesion score of placebo group during untreated (dotted grey 
line) and placebo treated (continuous grey line) season. Statistics is only indicated when 
significant. D. Monthly lesion score of vaccinated group during untreated (dotted grey line) and 
eIL-31-CuMVTT vaccinated (continuous black line) season. Statistics is only indicated when 
significant. E. Delta of monthly lesion scores post booster vaccination from previous IBH season 
subtracted by placebo or vaccine treated season. Mid-season booster indicated by arrow.
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